 |
|
|
| |
Anti-α4β7 antibody facilitates improved renal function during SIV infection in macaques
|
| |
| |
CROI 2024 March 3-6 Denver
Samuel D. Johnson1, Thomas A. Premeaux2, Nageswara Pilli3, Jianshi Yu3, Lishomwa C. Ndhlovu2, Maureen A. Kane3, and Siddappa N. Byrareddy1 1 Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
2 Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA
3 Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.[4] It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7),[4][5] blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.[6]
https://en.wikipedia.org/wiki/Vedolizumab
|
| |
|
|
|
|
|
